Nothing wrong I suppose in doing mouse study but making this out to be some sort of conclusive proof as the headline implies is a bit silly and a big stretch imo.
looking at the graphs, Nox actually was hardly any better than the inactive control, most of the “effect” was caused by the Lu psma , sure adding Nox added further 10 days apparently but all a bit weak as substantiation for an additive effect imo. Not sure FDA would get excited about any of this.
Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed, page-24
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
